Lung Cancer
Volume 56, Issue 2 , Pages 167-174 , May 2007

Differential regulation of RANTES and IL-8 expression in lung adenocarcinoma cells

  • Corinne Henriquet

      Affiliations

    • Institut National de la Santé et de la Recherche Médicale U454 – IFR3, 34295 Montpellier cedex 5, France
    • ,
  • Claire Gougat

      Affiliations

    • Institut National de la Santé et de la Recherche Médicale U454 – IFR3, 34295 Montpellier cedex 5, France
    • ,
  • Audrey Combes

      Affiliations

    • Institut National de la Santé et de la Recherche Médicale U454 – IFR3, 34295 Montpellier cedex 5, France
    • ,
  • Gwendal Lazennec

      Affiliations

    • Institut National de la Santé et de la Recherche Médicale U540 – IFR3, 34090 Montpellier, France
    • ,
  • Marc Mathieu

      Affiliations

    • Institut National de la Santé et de la Recherche Médicale U454 – IFR3, 34295 Montpellier cedex 5, France
    • Corresponding Author InformationCorresponding author at: Institut National de la Santé et de la Recherche Médicale U454, Hôpital Arnaud de Villeneuve, 34295 Montpellier cedex 5, France. Tel.: +33 467 41 52 13; fax: +33 467 63 28 55.

Received 14 August 2006 ,Revised 1 December 2006 ,Accepted 4 December 2006.

References 

  1. Garfinkel A. Cancer statistics and trends. In:  Holleb AI,  Fink DJ,  Murphy GP editor. American cancer society textbook of clinical oncology. Atlanta: American Cancer Society; 1991;p. 2–9
  2. Mountain CF. Lung cancer staging classification. Clin Chest Med. 1993;14:43–53
  3. Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE, et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res. 2002;8:3803–3812
  4. Mule JJ, Custer M, Averbook B, Yang JC, Weber JS, Goeddel DV, et al. RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther. 1996;7:1545–1553
  5. Kutubuddin M, Federoff HJ, Challita-Eid PM, Halterman M, Day B, Atkinson M, et al. Eradication of pre-established lymphoma using herpes simplex virus amplicon vectors. Blood. 1999;93:643–654
  6. Manes S, Mira E, Colomer R, Montero S, Real LM, Gomez-Mouton C, et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med. 2003;198:1381–1389
  7. Luboshits G, Shina S, Kaplan O, Engelberg S, Nass D, Lifshitz-Mercer B, et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 1999;59:4681–4687
  8. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res. 2001;7:285–289
  9. Adler EP, Lemken CA, Katchen NS, Kurt RA. A dual role for tumor-derived chemokine RANTES (CCL5). Immunol Lett. 2003;90:187–194
  10. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res. 2003;63:8360–8365
  11. Yuan A, Yang PC, Yu CJ, Chen WJ, Lin FY, Kuo SH, et al. Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med. 2000;162:1957–1963
  12. Arenberg DA, Kunkel SL, Polverini PJ, Glass M, Burdick MD, Strieter RM. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest. 1996;97:2792–2802
  13. Moore BB, Arenberg DA, Stoy K, Morgan T, Addison CL, Morris SB, et al. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol. 1999;154:1503–1512
  14. Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, Bar-Eli M, et al. Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res. 2000;60:2290–2299
  15. Salcedo R, Martins-Green M, Gertz B, Oppenheim JJ, Murphy WJ. Combined administration of antibodies to human interleukin 8 and epidermal growth factor receptor results in increased antimetastatic effects on human breast carcinoma xenografts. Clin Cancer Res. 2002;8:2655–2665
  16. Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, et al. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol. 2002;161:125–134
  17. Lee LF, Hellendall RP, Wang Y, Haskill JS, Mukaida N, Matsushima K, et al. IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol. 2000;164:2769–2775
  18. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540–550
  19. Mocellin S, Rossi CR, Pilati P, Nitti D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev. 2005;16:35–53
  20. Mackay HJ, Twelves CJ. Protein kinase C: a target for anticancer drugs?. Endocr Relat Cancer. 2003;10:389–396
  21. Koivunen J, Aaltonen V, Peltonen J. Protein kinase C (PKC) family in cancer progression. Cancer Lett. 2006;235:1–10
  22. Moriuchi H, Moriuchi M, Fauci AS. Nuclear factor-kappa B potently up-regulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J Immunol. 1997;158:3483–3491
  23. Freund A, Jolivel V, Durand S, Kersual N, Chalbos D, Chavey C, et al. Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene. 2004;23:6105–6114
  24. Vincent S, Marty L, Fort P. S26 ribosomal protein RNA: an invariant control for gene regulation experiments in eucaryotic cells and tissues. Nucleic Acids Res. 1993;21:1498
  25. Mathieu M, Gougat C, Jaffuel D, Danielsen M, Godard P, Bousquet J, et al. The glucocorticoid receptor gene as a candidate for gene therapy in asthma. Gene Ther. 1999;6:245–252
  26. Stein B, Rahmsdorf HJ, Steffen A, Litfin M, Herrlich P. UV-induced DNA damage is an intermediate step in UV-induced expression of human immunodeficiency virus type 1, collagenase, c-fos, and metallothionein. Mol Cell Biol. 1989;9:5169–5181
  27. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22:153–183
  28. Sizemore N, Lerner N, Dombrowski N, Sakurai H, Stark GR. Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem. 2002;277:3863–3869
  29. Faisst S, Meyer S. Compilation of vertebrate-encoded transcription factors. Nucleic Acids Res. 1992;20:3–26
  30. Vermeulen L, De Wilde G, Notebaert S, Vanden Berghe W, Haegeman G. Regulation of the transcriptional activity of the nuclear factor-kappaB p65 subunit. Biochem Pharmacol. 2002;64:963–970
  31. Kohn EA, Yoo CJ, Eastman A. The protein kinase C inhibitor Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res. 2003;63:31–35
  32. Koivunen J, Aaltonen V, Koskela S, Lehenkari P, Laato M, Peltonen J. Protein kinase C alpha/beta inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells. Cancer Res. 2004;64:5693–5701
  33. Paz-Ares L, Douillard JY, Koralewski P, Manegold C, Smit EF, Reyes JM, et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2006;24:1428–1434
  34. Schwartz GK, Jiang J, Kelsen D, Albino AP. Protein kinase C: a novel target for inhibiting gastric cancer cell invasion. J Natl Cancer Inst. 1993;85:402–407
  35. Zhang J, Anastasiadis PZ, Liu Y, Thompson EA, Fields AP. Protein kinase C (PKC) betaII induces cell invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling pathway. J Biol Chem. 2004;279:22118–22123
  36. Murray NR, Davidson LA, Chapkin RS, Clay Gustafson W, Schattenberg DG, Fields AP. Overexpression of protein kinase C betaII induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol. 1999;145:699–711

PII: S0169-5002(06)00633-7

doi: 10.1016/j.lungcan.2006.12.003

Lung Cancer
Volume 56, Issue 2 , Pages 167-174 , May 2007

Article Tools

* Image Usage & Resolution